ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Ampio Pharmaceuticals, Inc." (AMPE) Report Updated: Jun 24, 2017 | Print This Page

Get more stock ratings by Louis Navellier

"Ampio Pharmaceuticals, Inc." (AMPE)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Pharmaceuticals
Competitors: PAHC,ZTS,HSKA,SUPN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
June July August September October November December January February March April May

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Ampio Pharmaceuticals, Inc."© quotemedia

Company Profile

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and decreasing vascular permeability. Its lead product candidates in development include Ampion, which is in Phase III clinical trial for osteoarthritis of the knee; and Optina that is in Phase IIb clinical trial for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.